MANCHESTER, England, April 20, 2021 /PRNewswire/ -- Phagenesis Ltd, a private healthcare company offering an innovative treatment for dysphagia, announces successful treatment of intubation–induced ...
MANCHESTER, England, Oct. 10, 2022 /PRNewswire/ -- Phagenesis Ltd, today announced that the U.S. Food and Drug Administration (FDA) has granted a De Novo request for the Phagenyx ® Neurostimulation ...
Nestlé Health Science S.A. recently announced that it will acquire Manchester, England-based Phagenesis Ltd. in a staged acquisition. The Phagenyx® product includes a treatment catheter and a base ...
The Nestle logo is pictured on the company headquarters entrance building in Vevey, Switzerland February 18, 2016. REUTERS/Pierre Albouy - RTX27GML ZURICH (Reuters) - Nestle (NESN.S) announced a deal ...
MANCHESTER, England, Nov. 11, 2020 /PRNewswire/ -- Phagenesis Ltd, a leading innovator in the treatment of dysphagia, is pleased to announce today the publication of the largest and most complex study ...
Hosted on MSN
Pharyngeal electrical stimulation highlighted as important therapy for post-stroke dysphagia
The American Stroke Association (ASA) has formally recognised pharyngeal electrical stimulation (PES) as an important tool for post-stroke dysphagia (difficulty swallowing) treatment. In ASA’s 2026 ...
Biotechnology business Phagenesis today announced the first sales of its treatment for stroke victims with a seven-figure deal that will see it distributed initially in the UK and the United Arab ...
MANCHESTER, England, Oct. 10, 2022 /PRNewswire/ -- Phagenesis Ltd, today announced that the U.S. Food and Drug Administration (FDA) has granted a De Novo request for the Phagenyx Neurostimulation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results